1. |
Bodyweight-based heparin regimen is beneficial |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 2-2
&NA;,
Preview
|
PDF (1104KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
2. |
Impact of diabetes mellitus on ischemic heart disease management |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 3-4
Giulio Zuanetti,
Preview
|
PDF (2198KB)
|
|
摘要:
Increasing evidence indicates that a history of diabetes mellitus plays a major role in affecting survival of patients with ischaemic heart disease. Reviewing currently available data, the impact of diabetes is particularly striking in 2 clinical settings: percutaneous transluminal coronary angioplasty (PTCA) and acute myocardial infarction (MI). These issues were discussed at a Zeneca-sponsored satellite meeting (entitled ‘Hypertension and Diabetes’) of the 16th Scientific Meeting of the International Society of Hypertension [Glasgow, UK; June 1996].
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 4-4
&NA;,
Preview
|
PDF (1121KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 5-5
&NA;,
Preview
|
PDF (989KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 6-6
&NA;,
Preview
|
PDF (1084KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
6. |
Corticosteroid use often inappropriate |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 7-7
&NA;,
Preview
|
PDF (1029KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 8-8
&NA;,
Preview
|
PDF (1025KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
8. |
New therapeutic approaches for treating lymphomas |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 9-10
Larry Prescott,
Preview
|
PDF (2023KB)
|
|
摘要:
Immunotherapy could prove to be a valuable new tool for treating patients with lymphomas refractory to conventional therapy. The antitumour activities of the monoclonal antibody IDEC-C2B8 and an antigen-pulsed dendritic cell vaccine were equivalent to the activity of single-agent chemotherapy, while tolerability was much better, according to recent trial data. The results of these studies were reported at the Annual Meeting of the American Society of Clinical Oncology [Philadelphia, US; May 1996]. The latest findings relating to the new chemotherapeutic agent 506U were also presented.
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 11-11
&NA;,
Preview
|
PDF (997KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1043,
1996,
Page 12-12
&NA;,
Preview
|
PDF (1066KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|